Mark J. Gergen - 01 Feb 2022 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Feb 2022, 20:49:24 UTC
Next filing: 03 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+357,200		$0.000000	357,200	01 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Stock Option (Right to Buy)	Award	$0	+518,500		$0.000000	518,500	01 Feb 2022	Common Stock	518,500	$4.75	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	12.5% of the shares subject to the stock option will vest and become exercisable on the first anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.